Drugs / Antivipmyn
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT04470791 | Jan 2015 → Jul 2017 | snakebite envenomation | Hospital Juarez de Mexico | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00639951 Comparator | Jan 2008 → Jan 2009 | snakebite envenomation | Instituto Bioclon S.A. de C.V. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antivipmyn | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00639951 ↗ |
| Known as | F(ab)2 antivenom therapy | “F(ab)2 antivenom therapy (antivipmyn®).” NCT04470791 ↗ |
| Modality | Protein / enzyme biologic | “Crotalinae (pit viper) equine immune F(ab)2” NCT00639951 ↗ |
| Route | Intravenous | “solution IV, administered in 60 minutes” NCT00639951 ↗ |